What happened
Prestige BioPharma updated a previously disclosed supply contract with Teva Pharmaceuticals International GmbH, now worth US$842K, about 8.64% of its recent annual revenue, running through May 2026.
For context, this single contract equals about 8.64% of the company's most recent annual revenue.
| Counterparty | Teva Pharmaceuticals International GmbH |
|---|---|
| Contract value | US$842K |
| vs. recent revenue | 8.64% |
| Through | May 2026 (from Oct 2025) |
| Filed | 2026-03-13, [Amended] Supply contract signed |
| Source | DART rcept 20260313801595 → open original filing |
Source: DART. Information only, not investment advice.